Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Baxdrostat + Dapagliflozin in Chronic Kidney Disease and High Blood Pressure
NCT07222917Phase 2Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Dec 2025
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 9
01
Overview
A Phase 2 trial of baxdrostat, dapagliflozin in chronic kidney disease (CKD), hypertension (HTN), sponsored by AstraZeneca. Started Dec 2025; status: active, not recruiting.
02
Drugs
baxdrostatdapagliflozin
03
Conditions
chronic kidney disease (CKD)hypertension (HTN)
Beyond the preview
Go deeper on NCT07222917.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07222917.